A Retrospective Analysis of the Real-Life Utilization of Ranibizumab in Patients with Wet Age-Related Macular Degeneration from Portugal
Autor(a) principal: | |
---|---|
Data de Publicação: | 2017 |
Outros Autores: | , , , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
Texto Completo: | https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/8217 |
Resumo: | Introduction: Anti-vascular endothelial growth factor therapy has revolutionized the treatment of wet age-related macular degeneration; however, it is important to monitor actual use of ranibizumab and related treatment outcomes in routine practice.Material and Methods: This was a retrospective, observational study to monitor the 2-year outcomes following ranibizumab treatment for wet age-related macular degeneration in Portugal. Patients treated between January 2009 and December 2009 were retrospectively evaluated. All decisions were made by the treating physician in accordance with their usual routine clinical practice. The primary assessment was mean change in visual acuity score using Early Treatment Diabetic Retinopathy Study or Snellen equivalent.Results: A total of 128 patients with wet age-related macular degeneration were analyzed (mean age 79.4 years; mean visual acuity score 54.2 letters). Mean change in visual acuity score from baseline was –1.6 letters (n = 82) at year one and –5.1 letters (n = 72) at year two. The mean number of ranibizumab injections was 3.8 (year one) and 1.6 (year two). On average, patients attended 8.6 and 5.0 visits and optical coherence tomography was used in 75.0% of patients in year one and in 56.3% of patients in year two, respectively.Discussion: Despite a relatively high number of visits, including monitoring visits and use of optical coherence tomography - guided therapy, few injections were administered and visual acuity was not improved.Conclusion: These findings indicate that as-needed treatment resulted in under-dosing in a real-life setting in Portugal. Such limitations may also be related to increasing numbers of patients, resulting in clinic saturation. |
id |
RCAP_2743b0d936e5c9b8ab40c07a5733e08a |
---|---|
oai_identifier_str |
oai:ojs.www.actamedicaportuguesa.com:article/8217 |
network_acronym_str |
RCAP |
network_name_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository_id_str |
7160 |
spelling |
A Retrospective Analysis of the Real-Life Utilization of Ranibizumab in Patients with Wet Age-Related Macular Degeneration from PortugalAnálise Retrospetiva Sobre a Utilização em Contexto Real do Ranibizumab em Doentes com Degenerescência Macular da Idade Exsudativa em PortugalPortugalRanibizumabVisual AcuityWet Macular DegenerationAcuidade VisualDegenerescência Macular ExsudativaFactores de TempoPortugalRanibizumabIntroduction: Anti-vascular endothelial growth factor therapy has revolutionized the treatment of wet age-related macular degeneration; however, it is important to monitor actual use of ranibizumab and related treatment outcomes in routine practice.Material and Methods: This was a retrospective, observational study to monitor the 2-year outcomes following ranibizumab treatment for wet age-related macular degeneration in Portugal. Patients treated between January 2009 and December 2009 were retrospectively evaluated. All decisions were made by the treating physician in accordance with their usual routine clinical practice. The primary assessment was mean change in visual acuity score using Early Treatment Diabetic Retinopathy Study or Snellen equivalent.Results: A total of 128 patients with wet age-related macular degeneration were analyzed (mean age 79.4 years; mean visual acuity score 54.2 letters). Mean change in visual acuity score from baseline was –1.6 letters (n = 82) at year one and –5.1 letters (n = 72) at year two. The mean number of ranibizumab injections was 3.8 (year one) and 1.6 (year two). On average, patients attended 8.6 and 5.0 visits and optical coherence tomography was used in 75.0% of patients in year one and in 56.3% of patients in year two, respectively.Discussion: Despite a relatively high number of visits, including monitoring visits and use of optical coherence tomography - guided therapy, few injections were administered and visual acuity was not improved.Conclusion: These findings indicate that as-needed treatment resulted in under-dosing in a real-life setting in Portugal. Such limitations may also be related to increasing numbers of patients, resulting in clinic saturation.Introdução: A terapeutica com anti-factor de proliferação endotelial vascular revolucionou o tratamento da degenerescência macular da idade exsudativa; no entanto, é importante monitorizar o uso em contexto real do ranibizumab e os resultados associados ao tratamento na prática clínica corrente.Material e Métodos: Este foi um estudo observacional, retrospetivo, para monitorizar os resultados de dois anos, após o tratamento com ranibizumab para a da degenerescência macular da idade exsudativa em Portugal. Os doentes tratados entre janeiro de 2009 e dezembro de 2009 foram avaliados retrospetivamente. Todas as decisões foram tomadas pelo médico responsável pelo tratamento, em conformidade com a respetiva prática clínica corrente. A avaliação primária foi a alteração média na melhor acuidade visual corrigida utilizando a tabela ETDRS (Early Treatment of Diabetic Retinopathy Study) ou Snellen equivalente.Resultados: Foi analisado um total de 128 doentes com degenerescência macular da idade exsudativa (idade média de 79,4 anos; média de acuidade visual de 54,2 letras). A alteração média na melhor acuidade visual corrigida desde a situação basal foi de -1,6 letras (n = 82) no ano um e -5,1 letras (n = 72) no ano dois. O número médio de injeções de ranibizumab foi de 3,8 (ano um) e 1,6 (ano dois). Em média, os doentes tiveram entre 8,6 e 5,0 consultas e foi utilizada a tomografia de coerência ótica em 75,0% dos doentes no ano um e em 56,3% dos doentes no ano dois, respetivamente.Discussão: Apesar do número de consultas relativamente elevado, incluindo consultas de monitorização e de utilização de terapêutica guiada por tomografia de coerência ótica, foram administradas poucas injeções e não houve melhoria na acuidade visual.Conclusão: Em Portugal, num contexto real, estes achados indicam que o tratamento consoante as necessidades resultou numa dosagem insuficiente. Essas limitações também podem estar associadas ao número crescente de doentes, o que resulta numa saturação clínica.Ordem dos Médicos2017-06-30info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfapplication/mswordimage/tiffimage/tiffimage/tiffimage/tiffapplication/pdfapplication/mswordapplication/pdfapplication/pdfhttps://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/8217oai:ojs.www.actamedicaportuguesa.com:article/8217Acta Médica Portuguesa; Vol. 30 No. 6 (2017): June; 449-456Acta Médica Portuguesa; Vol. 30 N.º 6 (2017): Junho; 449-4561646-07580870-399Xreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAPenghttps://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/8217https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/8217/5073https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/8217/8757https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/8217/8758https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/8217/8759https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/8217/8760https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/8217/8761https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/8217/8795https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/8217/9066https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/8217/9195https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/8217/9198Direitos de Autor (c) 2017 Acta Médica Portuguesainfo:eu-repo/semantics/openAccessSilva, RufinoGoncalves, CarlaMeireles, AngelaTeixeira, CarlaRosa, PauloMonteiro-Grillo, ManuelCanelas, JoaquimCarneiro, AngelaFlores, Rita2022-12-20T11:05:27Zoai:ojs.www.actamedicaportuguesa.com:article/8217Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T16:19:33.610839Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse |
dc.title.none.fl_str_mv |
A Retrospective Analysis of the Real-Life Utilization of Ranibizumab in Patients with Wet Age-Related Macular Degeneration from Portugal Análise Retrospetiva Sobre a Utilização em Contexto Real do Ranibizumab em Doentes com Degenerescência Macular da Idade Exsudativa em Portugal |
title |
A Retrospective Analysis of the Real-Life Utilization of Ranibizumab in Patients with Wet Age-Related Macular Degeneration from Portugal |
spellingShingle |
A Retrospective Analysis of the Real-Life Utilization of Ranibizumab in Patients with Wet Age-Related Macular Degeneration from Portugal Silva, Rufino Portugal Ranibizumab Visual Acuity Wet Macular Degeneration Acuidade Visual Degenerescência Macular Exsudativa Factores de Tempo Portugal Ranibizumab |
title_short |
A Retrospective Analysis of the Real-Life Utilization of Ranibizumab in Patients with Wet Age-Related Macular Degeneration from Portugal |
title_full |
A Retrospective Analysis of the Real-Life Utilization of Ranibizumab in Patients with Wet Age-Related Macular Degeneration from Portugal |
title_fullStr |
A Retrospective Analysis of the Real-Life Utilization of Ranibizumab in Patients with Wet Age-Related Macular Degeneration from Portugal |
title_full_unstemmed |
A Retrospective Analysis of the Real-Life Utilization of Ranibizumab in Patients with Wet Age-Related Macular Degeneration from Portugal |
title_sort |
A Retrospective Analysis of the Real-Life Utilization of Ranibizumab in Patients with Wet Age-Related Macular Degeneration from Portugal |
author |
Silva, Rufino |
author_facet |
Silva, Rufino Goncalves, Carla Meireles, Angela Teixeira, Carla Rosa, Paulo Monteiro-Grillo, Manuel Canelas, Joaquim Carneiro, Angela Flores, Rita |
author_role |
author |
author2 |
Goncalves, Carla Meireles, Angela Teixeira, Carla Rosa, Paulo Monteiro-Grillo, Manuel Canelas, Joaquim Carneiro, Angela Flores, Rita |
author2_role |
author author author author author author author author |
dc.contributor.author.fl_str_mv |
Silva, Rufino Goncalves, Carla Meireles, Angela Teixeira, Carla Rosa, Paulo Monteiro-Grillo, Manuel Canelas, Joaquim Carneiro, Angela Flores, Rita |
dc.subject.por.fl_str_mv |
Portugal Ranibizumab Visual Acuity Wet Macular Degeneration Acuidade Visual Degenerescência Macular Exsudativa Factores de Tempo Portugal Ranibizumab |
topic |
Portugal Ranibizumab Visual Acuity Wet Macular Degeneration Acuidade Visual Degenerescência Macular Exsudativa Factores de Tempo Portugal Ranibizumab |
description |
Introduction: Anti-vascular endothelial growth factor therapy has revolutionized the treatment of wet age-related macular degeneration; however, it is important to monitor actual use of ranibizumab and related treatment outcomes in routine practice.Material and Methods: This was a retrospective, observational study to monitor the 2-year outcomes following ranibizumab treatment for wet age-related macular degeneration in Portugal. Patients treated between January 2009 and December 2009 were retrospectively evaluated. All decisions were made by the treating physician in accordance with their usual routine clinical practice. The primary assessment was mean change in visual acuity score using Early Treatment Diabetic Retinopathy Study or Snellen equivalent.Results: A total of 128 patients with wet age-related macular degeneration were analyzed (mean age 79.4 years; mean visual acuity score 54.2 letters). Mean change in visual acuity score from baseline was –1.6 letters (n = 82) at year one and –5.1 letters (n = 72) at year two. The mean number of ranibizumab injections was 3.8 (year one) and 1.6 (year two). On average, patients attended 8.6 and 5.0 visits and optical coherence tomography was used in 75.0% of patients in year one and in 56.3% of patients in year two, respectively.Discussion: Despite a relatively high number of visits, including monitoring visits and use of optical coherence tomography - guided therapy, few injections were administered and visual acuity was not improved.Conclusion: These findings indicate that as-needed treatment resulted in under-dosing in a real-life setting in Portugal. Such limitations may also be related to increasing numbers of patients, resulting in clinic saturation. |
publishDate |
2017 |
dc.date.none.fl_str_mv |
2017-06-30 |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/8217 oai:ojs.www.actamedicaportuguesa.com:article/8217 |
url |
https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/8217 |
identifier_str_mv |
oai:ojs.www.actamedicaportuguesa.com:article/8217 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/8217 https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/8217/5073 https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/8217/8757 https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/8217/8758 https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/8217/8759 https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/8217/8760 https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/8217/8761 https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/8217/8795 https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/8217/9066 https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/8217/9195 https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/8217/9198 |
dc.rights.driver.fl_str_mv |
Direitos de Autor (c) 2017 Acta Médica Portuguesa info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
Direitos de Autor (c) 2017 Acta Médica Portuguesa |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf application/msword image/tiff image/tiff image/tiff image/tiff application/pdf application/msword application/pdf application/pdf |
dc.publisher.none.fl_str_mv |
Ordem dos Médicos |
publisher.none.fl_str_mv |
Ordem dos Médicos |
dc.source.none.fl_str_mv |
Acta Médica Portuguesa; Vol. 30 No. 6 (2017): June; 449-456 Acta Médica Portuguesa; Vol. 30 N.º 6 (2017): Junho; 449-456 1646-0758 0870-399X reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação instacron:RCAAP |
instname_str |
Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
instacron_str |
RCAAP |
institution |
RCAAP |
reponame_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
collection |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository.name.fl_str_mv |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
repository.mail.fl_str_mv |
|
_version_ |
1799130645960589312 |